Biopharmaceutical stocks that have lagged behind the broader market may finally have their day in the sun. BofA Securities ...

Valued at a market cap of $143.8 billion, Gilead Sciences, Inc. (GILD ... becomes more evident when compared to its rival, Amgen Inc. (AMGN), which gained 14.4% over the past 52 weeks and 21.5 ...

Though Amgen has recouped much of that loss ... Gilead is a steady dividend stock with a high, growing payout David Jagielski (Gilead Sciences): Biopharmaceutical company Gilead Sciences can ...

Raffat covers the Healthcare sector, focusing on stocks such as Amgen, Eli Lilly & Co, and Biogen. Gilead Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $105. ...

BofA raised the firm’s price target on Gilead (GILD) to $126 from $116 and keeps a Buy rating on the shares. For the last several weeks, ...

Amgen profits rise, next MariTide studies ... Gilead 3rd-quarter results beat Wall Street estimates, raises outlook Gilead Sciences reported third-quarter financial results that handily beat ...

Gilead Sciences beat analysts’ revenue expectations ... beating analysts’ expectations by 1.9%, and Amgen reported revenues up 10.9%, topping estimates by 2.6%. AbbVie traded up 8.3% following ...

Read our full analysis of AbbVie’s results here and Amgen’s results here. Investors in the biotechnology segment have had steady hands going into earnings, with share prices flat over the last month.